<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621564</url>
  </required_header>
  <id_info>
    <org_study_id>LY2022-028-B</org_study_id>
    <nct_id>NCT05621564</nct_id>
  </id_info>
  <brief_title>Pre-operative Therapy in Breast Cancer</brief_title>
  <official_title>The Effect of Pre-operative Therapy on Response and Survival in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective and retrospective study to evaluate the effect of pre-operative therapy&#xD;
      on response and survival, and compare the difference in response and survival by&#xD;
      pre-operative regimen or by patient's clinicopathological characteristic in early or advanced&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2022</start_date>
  <completion_date type="Anticipated">November 2030</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response</measure>
    <time_frame>at surgery</time_frame>
    <description>ypT0 ypN0, ypT0/is ypN0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>from the start of pre-operative treatment until the completion of surgery up to 6 months</time_frame>
    <description>the rate of complete response and partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>From surgery until time of event up to 8 years</time_frame>
    <description>Disease-free survival time is defined as the time from date of randomization until the first occurrence of disease recurrence, distant metastasis and death from any cause.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">488</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>early breast cancer</arm_group_label>
    <description>no requirements for therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>advanced breast cancer</arm_group_label>
    <description>no requirements for therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pre-operative therapy</intervention_name>
    <description>pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy</description>
    <arm_group_label>advanced breast cancer</arm_group_label>
    <arm_group_label>early breast cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be selected from the hospital where they are treated&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, Aged â‰¥18 years&#xD;
&#xD;
          -  Histologically confirmed primary breast cancer&#xD;
&#xD;
          -  Plan to receive pre-operative therapy&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of neurological or psychological disease, including epilepsy or dementia&#xD;
&#xD;
          -  Not suitable to participate in this study judged by investigators&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenjin Yin</last_name>
    <phone>86(21)68385569</phone>
    <email>yinwenjin@renji.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital, School of Medicine, Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenjin Yin</last_name>
      <phone>86(21)68385569</phone>
      <email>yinwenjin@renji.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>March 23, 2023</last_update_submitted>
  <last_update_submitted_qc>March 23, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Wenjin Yin</investigator_full_name>
    <investigator_title>Deputy Chief of Breast Surgery Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

